良性前列腺增生手术与药物治疗的长期费用比较:基于医院账单数据的研究
该研究利用医院账单数据分析良性前列腺增生(BPH)长期药物治疗与早期手术的实际费用。长期药物治疗组137例,早期手术对照组70例。中位随访76个月时,药物治疗组总费用和自付费用均显著高于手术组,总费用在药物治疗第5年末与早期手术持平。
要点
- 长期药物治疗BPH的总费用和自付费用均显著高于早期手术。
- 药物治疗第5年末累计费用与早期手术费用持平。
- 药物相关费用占总费用和自付费用比例均超过一半。
核心结论
- 长期药物治疗BPH的累计费用高于早期手术,建议初始治疗时告知患者持续用药5年的自付费用可能超过早期手术。
研究设计与样本
- 长期药物治疗组(Group 1)定义为包含5α-还原酶抑制剂且最低药物持有率0.5持续≥5年,或直至因药物治疗失败接受BPH手术≥1年,共137例。
- 对照组(Group 2)为首次就诊后<1年内接受BPH手术的患者,共70例。
主要发现
- Group 1中4例(2.9%)在中位57.8个月后接受BPH手术。
- 中位随访76个月时,Group 1平均总治疗费用显著高于Group 2(3987美元 vs 3036美元,P < 0.001)。
- Group 1平均自付费用显著高于Group 2(1742美元 vs 1436美元,P = 0.005)。
- 假设Group 1年度BPH治疗费用线性增加且Group 2所有费用发生在第一年,则总费用和自付费用在药物治疗第5年末相等。
- 总费用和自付费用中,药物相关费用占比最大,超过一半。
临床怎么用
- 在BPH治疗开始时,应向患者说明持续药物治疗5年的累计自付费用可能超过早期手术。
- 利用电子医院管理系统提取的账单数据进行费用研究,可为医疗提供者和支付方提供有价值的信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To analyse actual long-term medical treatment of benign prostatic hyperplasia (BPH) and compare the incurred cost with that of patients with BPH who underwent early surgery. PATIENTS AND METHODS: Patients who were first diagnosed with BPH from 1 January 2008 to 31 December 2010 were identified using the Clinical Data Warehouse. Hospital billing data generated by the electronic hospital management system were collected until December 2015. For outpatient care, only procedures, materials and drugs directly related to the management of BPH were selected for the analysis. For inpatient care, all procedures, materials and drugs ordered on dates with continuity with BPH surgery date were included. The primary endpoint of the study was the total treatment-related direct costs of patients undergoing a long-term curative medical therapy for BPH (Group 1), which was arbitrarily defined as any medical therapy including a 5α-reductase inhibitor with a minimum medication possession ratio of 0.5 during ≥5 consecutive years, or ≥1 year until BPH surgery due to medical therapy failure. In all, 70 patients who underwent BPH surgery at <1 year of initial visit served as controls (Group 2). RESULTS: Amongst 137 patients in the Group 1, four patients underwent BPH surgery at a median of 57.8 months after the initial visit (2.9%). At a median follow-up of 76 months, the mean total treatment cost was significantly higher in Group 1 than in Group 2 ($3987 vs $3036 [USA dollars], P < 0.001). Similarly, the mean 'out-of-pocket' cost was significantly higher in Group 1 than in Group 2 ($1742 vs $1436, P = 0.005). When a linear increment of annual BPH treatment cost is assumed for Group 1 and all costs are assumed to be produced within the first year for Group 2, the total and out-of-pocket costs became equal at the end of the fifth year of medical treatment. For both total and out-of-pocket costs, medication-related costs occupied the largest proportion, exceeding half of the costs. CONCLUSIONS: We suggest patient counselling at the beginning of BPH treatment should include the likelihood that the cumulative out-of-pocket cost at 5 years of continuous medication will exceed that of early surgery. Our cost study using hospital billing data extractable from the electronic hospital management system may be a good model for cost studies that could provide valuable information to health providers and payers.
引用
- Ahn HS, Kim SJ, Choi JB, et al. Long-term cost comparison between surgical and medical therapy for benign prostatic hyperplasia: a study using hospital billing data. BJU Int. 2018. PMID: 30303597. doi:10.1111/bju.14584
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。